首页 | 本学科首页   官方微博 | 高级检索  
检索        

汉防己甲素对人鼻咽癌CNE1和CNE2细胞株的放疗增敏作用
引用本文:王君,常利红,李霞,陈贤珍,吴喜福,王志远,黄子真,黄健聪,张革化.汉防己甲素对人鼻咽癌CNE1和CNE2细胞株的放疗增敏作用[J].中国病理生理杂志,2017,33(9):1611-1618.
作者姓名:王君  常利红  李霞  陈贤珍  吴喜福  王志远  黄子真  黄健聪  张革化
作者单位:中山大学附属第三医院耳鼻咽喉头颈外科, 广东 广州 510630
基金项目:广东省自然科学基金资助项目(No.2014A030313142);广州市科技计划对外科技合作专项(No.2013J4500013);广州市天河区科技计划项目医疗卫生专项(No.2013KW027)
摘    要:目的:探讨最大非毒性剂量汉防己甲素(tetrandrine,Tet)对人鼻咽癌细胞株CNE1和CNE2的放疗增敏机制。方法:分别采用最大非毒性剂量Tet(对CNE1细胞为1.5μmol/L;对CNE2细胞为1.8μmol/L)、4 Gy放疗和最大非毒性剂量Tet联合放疗处理CNE1和CNE2细胞;流式细胞术检测各组细胞周期分布,Western blot检测各组细胞γ-H2AX、cleaved caspase-3、p-CDC25C、CDK1、p-CDK1、cyclin B1、ERK和p-ERK的蛋白水平。结果:最大非毒性剂量Tet联合放疗后可上调CNE1和CNE2细胞中γ-H2AX的表达。放疗组CNE1和CNE2细胞G_2/M期的比例分别为(18.09±0.42)%和(18.48±1.32)%,联合处理组CNE1和CNE2细胞G_2/M期的比例降为(15.88±1.04)%和(13.80±0.82)%,与放疗组比较差异有统计学意义(P0.05)。联合处理可增加放疗所致的cleaved caspase-3的蛋白水平(P0.05)。不同浓度Tet处理CNE1和CNE2细胞后,p-CDC25C和p-CDK1的蛋白水平随Tet浓度增加而升高(P0.05),CDK1的表达无明显改变;最大非毒性剂量Tet不影响p-CDC25C、p-CDK1和CDK1的蛋白水平。在CNE1和CNE2细胞中,联合处理可明显降低放疗引起的p-CDC25C和p-CDK1的蛋白水平(P0.05),上调放疗后cyclin B1的表达,而对总CDK1的表达无明显调节作用;联合处理可显著抑制放疗所致的pERK蛋白水平(P0.05)。结论:最大非毒性剂量Tet可以增加放疗引起的CNE1和CNE2细胞的DNA断裂及细胞凋亡,其放疗增敏的机制可能与Tet调控ERK/CDC25C/CDK1/cyclin B1通路、去除放疗导致的G2/M期阻滞有关。

关 键 词:汉防己甲素  鼻咽癌  G2/M期阻滞  ERK/CDC25C/CDK1/cyclin  B1通路  
收稿时间:2017-01-26

Effect of tetrandrine on radiosensitivity of nasopharyngeal carcinoma cells
WANG Jun,CHANG Li-hong,LI Xia,CHEN Xian-zhen,WU Xi-fu,WANG Zhi-yuan,HUANG Zi-zhen,HUANG Jian-cong,ZHANG Ge-hua.Effect of tetrandrine on radiosensitivity of nasopharyngeal carcinoma cells[J].Chinese Journal of Pathophysiology,2017,33(9):1611-1618.
Authors:WANG Jun  CHANG Li-hong  LI Xia  CHEN Xian-zhen  WU Xi-fu  WANG Zhi-yuan  HUANG Zi-zhen  HUANG Jian-cong  ZHANG Ge-hua
Institution:Department of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
Abstract:AIM: To investigate the mechanism of the radiosensitizing effect of maximum non-cytotoxic doses of tetrandrine (Tet) on nasopharyngeal carcinoma cell lines CNE1 and CNE2.METHODS: The cells were treated with ma-ximum non-cytotoxic doses of Tet (for CNE1 cells at 1.5 μmol/L and for CNE2 cells at 1.8 μmol/L), irradiation at 4 Gy, or combination of irradiation and maximum non-cytotoxic doses of Tet. The cell cycle distribution was analyzed by flow cytometry. The protein levels of γ-H2AX, cleaved caspase-3, p-CDC25C, CDK1, p-CDK1, cyclin B1, ERK and p-ERK were determined by Western blot.RESULTS: The expression of γ-H2AX was increased in CNE1 cells and CNE2 cells after combined treatment with irradiation and maximum non-cytotoxic doses of Tet. The percentages of CNE1 cells and CNE2 cells at G2/M phase in irradiation group were (18.09±0.42)% and (18.48±1.32)%, respectively, which were decreased to (15.88±1.04)% and (13.80±0.82)% in combined treatment group, respectively (P<0.05). Combined treatment enhanced the increase in the protein level of cleaved caspase-3 caused by irradiation. The protein levels of p-CDC25C and p-CDK1 were increased in a dose-dependent manner by Tet treatment (P<0.05), while the expression of CDK1 showed no difference among different doses of Tet treatments. The protein levels of p-CDC25C, p-CDK1 and CDK1 showed no difference after the treatment with maximum non-cytotoxic doses of Tet. The combined treatment with irradiation and the maximum non-cytotoxic doses of Tet decreased the protein levels of p-CDC25C and p-CDK1 (P<0.05), increased the expression of cyclin B1, and had no influence on the expression of CDK1 (P<0.05). The combined treatment resulted in an increase in the protein level of p-ERK1 (P<0.05).CONCLUSION: The maximum non-cytotoxic doses of Tet enhance the DNA damage and apoptosis in CNE1 cells and CNE2 cells caused by irradiation, and the mechanism might be associated with ending of G2/M arrest via activation of ERK/CDC25C/CDK1/cyclin B1 pathways.
Keywords:Tetrandrine  Nasopharyngeal carcinoma  G2/M phase arrest  ERK/CDC25C/CDK1/cyclin B1 pathways
本文献已被 CNKI 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号